News Potential 10-22-15/ PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
## source: finance.yahoo.com
Thu, 22 Oct 2015 11:50:00 GMT ~ Small Cap Companies Exceed Expectations in Volatile Markets, with Penny Plays Showing Investors Huge Potential
[Accesswire] - DELRAY BEACH, FL / ACCESSWIRE / October 22, 2015 / Across the board, savvy investors have shown an interest in small caps low-priced shares in exchange for a possible large potential return. In an uncertain ...
Wed, 21 Oct 2015 16:16:18 GMT ~ PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
[at noodls] - SILVER SPRING, Md., Oct. 21, 2015 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
Wed, 21 Oct 2015 13:20:00 GMT ~ PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
[GlobeNewswire] - SILVER SPRING, Md., Oct. 21, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
Tue, 20 Oct 2015 13:15:00 GMT ~ PharmaCyte Biotech's Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments
[PR Newswire] - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. In the article, analyst Rob Goldman notes that the use of encapsulation techniques to treat Type 1 diabetes (T1D) has become a viable and high profile approach in recent months, with the support and funding of the Juvenile Diabetes Research Foundation (JDRF).
Mon, 19 Oct 2015 13:49:14 GMT ~ PharmaCyte Biotech to Conduct Pancreatic Cancer Clinical Trial in United States
[GlobeNewswire] - SILVER SPRING, Md., Oct. 19, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
Link: http://www.otcmarkets.com/stock/PMCB/company-info Ticker: $PMCB OTC Market Place: OTCQB CIK code: 0001157075 Company name: PharmaCyte Biotech, Inc. Company website: http://http://www.PharmaCyte.com Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $85,122,578 a/o Oct 21, 2015 Shares Outstanding: 743,428,629 a/o Aug 24, 2015 Float: 529,206,849 a/o Aug 26, 2014 Authorized Shares: 1,490,000,000 a/o Aug 26, 2014 Par Value: 0.0001